Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2001-11-15
2010-02-16
Angell, J. E (Department: 1635)
Chemistry: molecular biology and microbiology
Vector, per se
C514S04400A
Reexamination Certificate
active
07662619
ABSTRACT:
The present invention provides an isolated nucleic acid comprising the nucleotides set forth in the Sequence Listing as SEQ ID NO: 1. SEQ ID NO: 1 is an example of GP64-6His nucleic acid. The invention further provides polypeptides encoded by GP64-6His nucleic acids as well as the polypeptide encoded by SEQ ID NO: 2. The invention also provides liposomes comprising GP64-6His polypeptides as well as liposomes comprising GP64-6His polypeptides and biological molecules. The invention further provides a method of increasing the solubility of polypeptides comprising linking a 6His tag to a polypeptide and measuring the solubility of the 6His-tagged polypeptide, whereby an increase in solubility of the 6His-tagged polypeptide can be detected. The invention also provides a method of solubilizing a viral fusion polypeptide comprising linking a 6His tag to a viral fusion polypeptide. Further provided is a method of delivering a biological molecule to a cell comprising, administering the liposome comprising a GP64-6His polypeptide to a cell. This invention also provides a method of delivering a viral vaccine to a cell comprising administering the liposome comprising a GP64-6His polypeptide to a cell. Also provided is a method of delivering a DNA vaccine to a cell comprising administering the liposome comprising a GP64-6His polypeptide to a cell. Further provided is a GP64-6His polypeptide further comprising a binding site for a cell surface molecule. Also provided by this invention are chimeric proteins comprising GP64-6His.
REFERENCES:
patent: 5919480 (1999-07-01), Kedar et al.
patent: 6001806 (1999-12-01), Murphy et al.
patent: 6261554 (2001-07-01), Valerio et al.
patent: WO 9965465 (1999-12-01), None
patent: WO 00/64471 (2000-11-01), None
patent: WO 01/93836 (2001-12-01), None
Qiagen Product Guide, 1998; pp. 40-45.
Mullins et al. (1996) J. Clin. Invest. vol. 98, pp. 1557-1560.
Mullins et al. (1993) Hypertension vol. 22, pp. 630-633.
Cameron (1997) Molec. Biotech. vol. 7, pp. 253-265.
Kappel et al. (1992) Current Opinion in Biotechnology, vol. 3, pp. 548-553.
Massotte et al. (Jour. Biotech. 1999, vol. 69, pp. 39-45).
Lian et al. (J. Pharm. Sci. 2001, vol. 90, pp. 667-680).
Miller et al. (FASEB J. 1995, vol. 9, pp. 190-199).
Ambrosch. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine.Vaccine. 15(11):1209-1213 (1997).
Gould-Fogerite et al. Chimerasome-mediated gene transfer in vitro and in vivo.Gene. 84:429-438 (1989).
Gregoriadis. Genetic vaccines: strategies for optimization.Pharm Res. 15(5):661-670 (1998).
Hollister. Stable expression of mammalian β1,4-galactosyltransferase extends tha N-glycosylation pathway in insect cells..Glycobiology. 8(5):473-480 (1998).
Ishii et al. Cationic liposomes are a strong adjuvant for a DNA vaccine of human immunodeficiency virus type 1.AidsRes. Hum. Retroviruses 13(16):1421-1428 (1997).
Jarvis et al. Biosynthesis and Processing of theAutographa californicaNuclear Polyhedrosis Virus GP64 Protein.Virology. 205:300-313 (1994).
Kedar et al. Delivery of Cytokines by Liposomes. II. Interleukin-2 Encapsulated in Long-Circulating Sterically Stabilized Liposomes: Immunomodulatory and Anti-tumor Activity in Mice.J Immunotherp. 16:115-124 (1994).
Naruse. A potential peptide vaccine against two different strains of influenze virus isolated at intervals of about 10 years.PNAS. 91:9588-9592 (Sep. 1994).
Okada. Intranasal Immunization of a DNA Vaccine with IL-12 and Granuloctye-Macrophage Colony-Stimulating Factor (GM-CSF)-Expressing Plasmids in Liposomes Induces Strong Mucosal and Cell-Mediated Immune Responses Against HIV-1 Antigens.J. Immunol. 159:3638-3647 (1997).
Vaage et al. Therapy of a xenografted human colonic carcinoma using cisplatin or doxorubicin encapsulated in long-circulating pegylated stealth liposomes.Int J Cancer. 80:134-137 (1999).
Vertut-Doi et al. Binding and uptake of liposomes containing a poly(ethylene glycol) derivative of cholesterol (stealth liposomes) by the macrophage cell line J774: influence of PEG content and its molecular weight.Biochim Biophys Acta. 1278:19-28 (1996).
Working et al. Reduction of the Cardiotoxicity of Doxorubicin in Rabbits and Dogs by Encapsulation in Long-Circulating, Pegylated Liposomes.J Pharmacol Exp Ther. 289(2):1128-1133 (1999).
Kingsley et al., “A discrete stage of baculovirus GP64-medicated membrane fusion” Molecular Biology of the Cell 10(12):4191-4200 (1999).
Monsma et al., “Identification of a membrane fusion domain and an oligomerization domain in the baculovbirus GR64 envelope fusion protein” J. Virology 69(4):2583-2595 (1995).
Plonsky et al. “An Analysis of the Role of the Target Membrane on the GP64 induced fusion pore” Virology 253(1):65-76 (1999).
Kingsley David H.
Zimmerberg Joshua
Angell J. E
The United States of America as represented by the Secretary of
Townsend and Townsend / and Crew LLP
LandOfFree
Sol-fusin: use of GP64-6His to catalyze membrane fusion does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sol-fusin: use of GP64-6His to catalyze membrane fusion, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sol-fusin: use of GP64-6His to catalyze membrane fusion will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4226900